JP2005506285A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506285A5
JP2005506285A5 JP2002567353A JP2002567353A JP2005506285A5 JP 2005506285 A5 JP2005506285 A5 JP 2005506285A5 JP 2002567353 A JP2002567353 A JP 2002567353A JP 2002567353 A JP2002567353 A JP 2002567353A JP 2005506285 A5 JP2005506285 A5 JP 2005506285A5
Authority
JP
Japan
Prior art keywords
egfr
retinoid
retinoic acid
use according
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002567353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506285A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/006175 external-priority patent/WO2002067988A2/en
Publication of JP2005506285A publication Critical patent/JP2005506285A/ja
Publication of JP2005506285A5 publication Critical patent/JP2005506285A5/ja
Pending legal-status Critical Current

Links

JP2002567353A 2001-02-27 2002-02-27 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用 Pending JP2005506285A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27189401P 2001-02-27 2001-02-27
PCT/US2002/006175 WO2002067988A2 (en) 2001-02-27 2002-02-27 Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008216055A Division JP2009079038A (ja) 2001-02-27 2008-08-26 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用

Publications (2)

Publication Number Publication Date
JP2005506285A JP2005506285A (ja) 2005-03-03
JP2005506285A5 true JP2005506285A5 (https=) 2005-06-30

Family

ID=23037535

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002567353A Pending JP2005506285A (ja) 2001-02-27 2002-02-27 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用
JP2008216055A Pending JP2009079038A (ja) 2001-02-27 2008-08-26 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008216055A Pending JP2009079038A (ja) 2001-02-27 2008-08-26 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用

Country Status (8)

Country Link
US (2) US6638543B2 (https=)
EP (1) EP1370294A2 (https=)
JP (2) JP2005506285A (https=)
AU (1) AU2002255627B2 (https=)
BR (1) BR0207663A (https=)
CA (1) CA2439408C (https=)
MX (1) MXPA03007609A (https=)
WO (1) WO2002067988A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US20040047828A1 (en) * 1998-08-01 2004-03-11 Merck Patent Gmbh Ectoin or ection derivatives and surfactants
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US7048910B2 (en) 2000-09-07 2006-05-23 Merck Patent Gmbh Use of ectoine or ectoine derivatives for oral care
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
KR100358819B1 (ko) * 2001-06-12 2002-10-25 김기홍 생약 패취제
DE10214257A1 (de) * 2002-03-28 2003-10-16 Merck Patent Gmbh Verwendung von kompatiblen Soluten zur Inhibierung der Freisetzung von Ceramiden
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
CN104643057A (zh) 2002-07-24 2015-05-27 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
EP1545451A1 (en) * 2002-09-07 2005-06-29 Johnson & Johnson Consumer France SAS Compositions comprising soy products and organic salts of certain metals
EP1542654A4 (en) * 2002-09-23 2008-12-17 Novogen Res Pty Ltd TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7498127B2 (en) * 2002-12-20 2009-03-03 Shigeki Higashiyama Method of screening cell growth inhibitor and cell growth inhibitor
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
CA2564399A1 (en) * 2004-04-28 2005-11-17 Brigham Young University Use of equol for treating skin diseases
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
JP2008528448A (ja) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
US20070042026A1 (en) * 2005-03-17 2007-02-22 Wille John J Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
FR2894821B1 (fr) * 2005-12-15 2008-02-29 Galderma Res & Dev Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations
JP5023323B2 (ja) * 2006-06-13 2012-09-12 国立大学法人 熊本大学 アクアポリン５の発現亢進剤
JP2010504974A (ja) * 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
US20080118449A1 (en) * 2006-11-21 2008-05-22 Alvin Ronlan Cosmetic formulations of piceatannol and retinoids and methods of use thereof
JP5746807B2 (ja) * 2006-12-28 2015-07-08 アルロン・ジャパン株式会社 皮膚用化粧品の組成物
JP5699414B2 (ja) * 2007-02-28 2015-04-08 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイション レチノイン酸療法の効力を妨げることなくレチノイン酸療法の副作用を軽減する方法、および／又は、その効力を改善する方法
US8666671B2 (en) * 2007-07-05 2014-03-04 Enhanced Pharmaceuticals, Inc. Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs
CA2713610C (en) * 2009-10-02 2019-08-20 Monash University Ectopic pregnancy treatment
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
WO2020136650A1 (en) * 2018-12-25 2020-07-02 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an egfr inhibitor
EP4003299A4 (en) * 2019-07-24 2023-08-23 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
KR20220097429A (ko) * 2019-11-06 2022-07-07 솔-겔 테크놀로지스 리미티드 손발바닥각피증 치료 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2124059A (en) 1982-07-09 1984-02-08 Gen Electric Co Plc Signal distribution networks
JPH06312919A (ja) * 1993-05-06 1994-11-08 Kao Corp 美白剤及びこれを含有する皮膚化粧料
DE4444238A1 (de) 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5824702A (en) 1996-06-07 1998-10-20 Mount Sinai School Of Medicine Of The City University Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
US5665367A (en) * 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
DE69719528T2 (de) * 1996-09-27 2003-11-06 Unilever Nv Hautpflegemittel enthaltend kombinationen aus verbindungen die die wirkungvon retinsaüre auf der haut nachbilden
EP0882717B1 (en) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
DE19713092A1 (de) * 1997-03-27 1998-10-01 Wacker Chemie Gmbh Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
FR2782919B1 (fr) * 1998-09-04 2001-05-25 Roc Sa Composition contre le vieillissement et son utilisation
KR100332031B1 (ko) 1999-06-03 2002-04-10 서경배 피부 주름의 개선 및 생성 억제 효과를 갖는 외용제 조성물
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators

Similar Documents

Publication Publication Date Title
JP2005506285A5 (https=)
US9782334B2 (en) Systems and methods for skin rejuvenation
CA2439408A1 (en) Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor
US5703122A (en) Ascorbic acid compositions for reducing irritation of topically applied active ingredients
Reszko et al. Cosmeceuticals: practical applications
Glaser Anti-aging products and cosmeceuticals
US20020127256A1 (en) Compositions and methods for treating dermatological disorders
US20070269537A1 (en) Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
US8232417B1 (en) Artemisinin derivatives with natural amino acids, peptides, and amino sugars for skin imperfections and infection in mammals
JP2006505583A5 (https=)
Draelos Cosmeceuticals for rosacea
EP2059221A1 (en) Skin care composition
US8193376B2 (en) Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals
US20100291190A1 (en) Topical Composition For Anti-Aging Skin Treatment Using Dual DNA Repair Mechanism and Method of Use
KR20010089781A (ko) 콩을 이용한 탈색 및 피부 보호 조성물
Bellad et al. Development ofcosmeceuticals
US9968546B2 (en) Topical composition for skin treatment to reduce lines and wrinkles of the face and body using a dual DNA repair mechanism to address damage caused by aging and ultra-violet induced damage to the skin with combination of skin turgor enhancement compounds
US8394851B2 (en) Osmoprotective complexes for prevention of mitochondrial free radical damage related skin aging
JP2004515460A5 (https=)
EP1694337A2 (en) Topical use of halosalicylic acid derivatives
US20030091666A1 (en) Methods and compositions for treating dermatological disorders with Morinda citrifolia
US20110124573A1 (en) Osmoprotective Complexes for Prevention of Intra-cellular Dehydration in Mammals
Burke Antiaging Regimens
JP2008533112A (ja) 特に酒さの治療のためのアベルメクチンとアゼライン酸に基づく組成物
JP2008534524A5 (https=)